title: Effect of H. pylori density by histopathology on its complications and eradication therapy.
abstract: BACKGROUND
  Helicobacter pylori (H. pylori) infection causes chronic gastritis and is a major risk factor for duodenal and gastric ulceration, gastric adenocarcinoma, and primary gastric lymphoma. Increased gastric bacterial density may lead to increased levels of inflammation and epithelial injury.
  
  
  OBJECTIVE
  1) To study the effect of H. pylori density by histological changes in stomach. 2) To study the effect of H. pylori density on the efficacy of standard triple drug eradication treatment. 3) To study the effect of H. pylori density on the complication related to H. pylori.
  
  
  METHODS
  All the patients visiting gastroenterology OPD with the symptoms of dyspepsia not responding to proton pump inhibitor or having alarm symptoms were subjected to upper GI endoscopy and biopsy. If H. pylori was present they were included in the study. The patients were given standard 14 day triple antibiotic combination for H. pylori eradication. H. pylori eradication was confirmed by urea breath test after six weeks of completion of treatment.
  
  
  RESULTS
  Out of 250 patients screened, 120 patients enrolled in the study. On clinical history 41.5% patients had symptoms of heart burn where as 63.3% patients had dyspeptic symptoms. Success rate of anti H. pylori triple drug therapy was 80%. Rate of eradication was significantly lower among the patients with higher H. pylori density (p < 0.05) on histopathology by Sydney classification. Duodenal ulcer, Gastric ulcer and gastric erosion were noted in higher frequencies among the patients with higher H. pylori density (p < 0.05).
  
  
  CONCLUSIONS
  H. pylori density by histopathology correlates with the complication related to H. pylori i.e. duodenal ulcer, reflux esophagitis and antral erosions. It also correlates with the success of the standard triple drug eradication treatment.
authors.forename: Dharmesh K
authors.initials: DK
authors.lastname: Shah
authors.forename: Samit S
authors.initials: SS
authors.lastname: Jain
authors.forename: Ashok
authors.initials: A
authors.lastname: Mohite
authors.forename: Anjali D
authors.initials: AD
authors.lastname: Amarapurkar
authors.forename: Q Q
authors.initials: QQ
authors.lastname: Contractor
authors.forename: Pravin M
authors.initials: PM
authors.lastname: Rathi
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001944:Breath Tests; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000209:etiology / Q000473:pathology / Q000628:therapy; D005260:Female; D005767:Gastrointestinal Diseases / Q000382:microbiology / Q000473:pathology* / Q000628:therapy; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D000077402:Pantoprazole; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D000077402:Pantoprazole; D017291:Clarithromycin